Heron Therapeutics (HRTX) Notes Payables (2011 - 2025)

Heron Therapeutics' (HRTX) quarterly Notes Payables came in at $149.8 million in Q2 2025, up 1882.87% on a QoQ basis from $7.6 million in Q1 2021.

Heron Therapeutics (HRTX) Notes Payables (2011 - 2025) Analysis & Trends

Heron Therapeutics (HRTX) has 12 years of Notes Payables data on file, last reported at $149.8 million in Q2 2025.

Quarterly Notes Payables changed N/A year-over-year to $149.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $149.8 million (changed N/A YoY) and the FY2020 annual result came in at $7.1 million, up 25.41% from the prior year.
Notes Payables grew to $149.8 million in Q2 2025, from $7.6 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $149.8 million in Q2 2025 to a low of $7.6 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Heron Therapeutics	58.32 Mn	15.65 Mn	26.09 Mn

Download Data